{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:17Z","timestamp":1787020877477,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Omeprazole belongs to the pharmacological classifications of proton pump inhibitors and is a widely used medicine. All proton pump inhibitors have a common mechanism of action and are prodrugs that require activation in an acidic environment. Omeprazole is extensively metabolized in the liver by cytochrome 2C19 and cytochrome 3A4, which are responsible for drug interactions. Omeprazole-induced galactorrhea is a rare adverse event of drug metabolism and is often underreported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This is a case of a 26-year-old unmarried Asian (Bhutanese) female who underwent kidney transplant and was administered standard antirejection medication (tacrolimus, prednisolone, and leflunomide) along with an antihypertensive agent. She came to the emergency department with complaints of nausea, vomiting, abdominal pain, chronic gastritis, anemia, hypertension, and loss of appetite. The tacrolimus trough level was in the subtherapeutic range at admission. The tacrolimus dose was adjusted, and oral omeprazole was administered. After 3\u00a0days, she experienced milk production from her left breast, which according to the patient was her second incidence after omeprazole ingestion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Causality assessment using Naranjo\u2019s algorithm and recovering from galactorrhea after stopping omeprazole and omeprazole rechallenge with the reappearance of galactorrhea confirmed omeprazole as the causative agent. Tacrolimus interferes with omeprazole metabolism and increases tacrolimus levels in the blood. Caution needs to be taken when omeprazole is administered with other drugs that interfere with metabolizing enzymes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-022-03337-3","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T20:04:22Z","timestamp":1648325062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Omeprazole-induced galactorrhea in kidney transplant patients\u2014a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-660X","authenticated-orcid":false,"given":"Choki","family":"Dorji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farruk Ahammed","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesara","family":"Na-Bangchang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"issue":"6","key":"3337_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528\u201334.","journal-title":"Curr Gastroenterol Rep"},{"issue":"8","key":"3337_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"XQ Li","year":"2004","unstructured":"Li XQ, Andersson TB, Ahlstr\u00f6m M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3337_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1365-2036.17.s1.2.x","volume":"17","author":"J Dent","year":"2003","unstructured":"Dent J. Review article: Pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther Suppl. 2003;17(1):5\u20139.","journal-title":"Aliment Pharmacol Ther Suppl."},{"issue":"12","key":"3337_CR4","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"P Miner","year":"2003","unstructured":"Miner P. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3337_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2515\/therapie:2003023","volume":"58","author":"A Peit","year":"2003","unstructured":"Peit A, Piednoir D, Germain ML, Trenque T. Drug-induced hyperprolactinaemia: a case\/non-case study in the French pharmacovigilance database. Therapies. 2003;58(2):159\u201363.","journal-title":"Therapies"},{"issue":"5","key":"3337_CR6","first-page":"929","volume":"3","author":"D La Torre","year":"2007","unstructured":"La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5):929\u201351.","journal-title":"Ther Clin Risk Manag"},{"issue":"SUPPL","key":"3337_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"RG Petty","year":"1999","unstructured":"Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999;35(SUPPL):67\u201373.","journal-title":"Schizophr Res"},{"issue":"2 SUPPL","key":"3337_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0269216307087148","volume":"22","author":"P Fitzgerald","year":"2008","unstructured":"Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 SUPPL):12\u20139.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"3337_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4065\/80.8.1050","volume":"80","author":"ME Molitch","year":"2005","unstructured":"Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"3337_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.npp.1300412","volume":"29","author":"E Ab","year":"2004","unstructured":"Ab E, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin\u2013prolactin interactions. Neuropsychopharmacology. 2004;29(5):833\u201346.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"3337_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1210\/endo.133.2.8344205","volume":"133","author":"PA Rittenhouse","year":"1993","unstructured":"Rittenhouse PA, Levy AD, Li Q, Bethea CL, Van de Kar LD. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c\/2 receptors. Endocrinology. 1993;133(2):661\u20137.","journal-title":"Endocrinology"},{"issue":"7","key":"3337_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","volume":"24","author":"F Coker","year":"2012","unstructured":"Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia. CNS Drugs. 2012;24(7):563\u201374.","journal-title":"CNS Drugs"},{"issue":"3","key":"3337_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4306\/pi.2017.14.3.368","volume":"14","author":"YM Park","year":"2017","unstructured":"Park YM. Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study. Psychiatry Investig. 2017;14(3):368\u201371.","journal-title":"Psychiatry Investig"},{"issue":"11","key":"3337_CR14","first-page":"1073","volume":"85","author":"W Huang","year":"2012","unstructured":"Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Physician. 2012;85(11):1073\u201380.","journal-title":"Am Fam Physician"},{"issue":"3","key":"3337_CR15","first-page":"104","volume":"1\u20132","author":"MD Bronstein","year":"2015","unstructured":"Bronstein MD. Disorders of prolactin secretion and prolactinomas. Endocrinol Adult Pediatr. 2015;1\u20132(3):104-128.e6.","journal-title":"Endocrinol Adult Pediatr."},{"issue":"3","key":"3337_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1210\/jcem-47-3-675","volume":"47","author":"T Taono","year":"1978","unstructured":"Taono T, Shioji T, Kinugasa T, Onishi T, Kurachi K. Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab. 1978;47(3):675\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3337_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000179051","volume":"11","author":"EI Tamagna","year":"1979","unstructured":"Tamagna EI, Lane W, Hershman JM, Carlson HE, Sturdevant RAL, Poland RE, et\u00a0al. Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res Paediatr. 1979;11(4):161\u20139.","journal-title":"Horm Res Paediatr"},{"key":"3337_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/gut.20.2.154","volume":"20","author":"RW Spence","year":"1979","unstructured":"Spence RW, Celestin LR. Gynaecomastia associated with cimetidine. Gut. 1979;20:154\u20137.","journal-title":"Gut"},{"issue":"6927","key":"3337_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1136\/bmj.308.6927.503","volume":"308","author":"LG Rodr\u00edguez","year":"1994","unstructured":"Rodr\u00edguez LG. Jick H Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ. 1994;308(6927):503.","journal-title":"BMJ"},{"issue":"8025","key":"3337_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(77)91358-7","volume":"1","author":"GF Delle Fave","year":"1977","unstructured":"Delle Fave GF, Tamburrano G, De Magistris L, Natoli C, Santoro ML, Carratu R, et\u00a0al. Gynaecomastia with cimetidine. Lancet (London, England). 1977;1(8025):1319.","journal-title":"Lancet (London, England)."},{"key":"3337_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8108730","volume":"2020","author":"M Prikis","year":"2020","unstructured":"Prikis M, MacDougall J, Narasimhadevara N. Proton pump inhibitor-induced galactorrhea in a kidney transplant recipient: a friend or foe? Case Rep Transplant. 2020;2020:1\u20135.","journal-title":"Case Rep Transplant."},{"issue":"1","key":"3337_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12328-015-0622-7","volume":"9","author":"N Pipaliya","year":"2016","unstructured":"Pipaliya N, Solanke D, Rathi C, Patel R, Ingle M, Sawant P. Esomeprazole induced galactorrhea: a novel side effect. Clin J Gastroenterol. 2016;9(1):13\u20136.","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"3337_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00003088-199631010-00002","volume":"31","author":"T Andersson","year":"1996","unstructured":"Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31(1):9\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3337_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003088-200140060-00003","volume":"40","author":"T Andersson","year":"2001","unstructured":"Andersson T, Hassan-Alin M, Hasselgren G, R\u00f6hss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(6):411\u201326.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3337_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1211\/0022357043914","volume":"56","author":"F Itagaki","year":"2004","unstructured":"Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, et\u00a0al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56(8):1055\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3337_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/endo-124-1-279","volume":"124","author":"JD Shull","year":"1989","unstructured":"Shull JD, Gorski J. Oestrogen regulation of prolactin gene transcription in vivo: paradoxical effects of 17 beta-oestradiol dose. Endocrinology. 1989;124(1):279\u201385.","journal-title":"Endocrinology"},{"issue":"4","key":"3337_CR27","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/B978-012515400-0\/50037-3","volume":"80","author":"KA Gregerson","year":"2006","unstructured":"Gregerson KA. Prolactin: structure, function, and regulation of secretion. Knobil Neill\u2019s Physiol Reprod. 2006;80(4):1703\u201326.","journal-title":"Knobil Neill\u2019s Physiol Reprod."},{"issue":"8","key":"3337_CR28","first-page":"689","volume":"60","author":"A Jabbar","year":"2010","unstructured":"Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. JPMA. 2010;60(8):689\u201390.","journal-title":"JPMA"},{"issue":"6","key":"3337_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0212-6567(04)79506-2","volume":"34","author":"IOM Prieto","year":"2004","unstructured":"Prieto IOM, Moreno AE. Galactorrea inducida por lansoprazol. Aten Primaria. 2004;34(6):325\u20136.","journal-title":"Aten Primaria"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03337-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T20:04:27Z","timestamp":1648325067000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03337-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3337"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03337-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Board of Health (REBH), Ministry of Health of Bhutan under reference no. REBH\/Approval\/2021\/098, and the Medical Education and Research Unit (MERU) of Jigme Dorji Wangchuk National Referral Hospital under approval reference no. JDWNRH\/MERU\/01\/2020-2021\/292 dated on 19 July 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CD, FAR, and KN-B have no conflicts of interest to declare that are relevant to the content of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}